Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany

References

• Steppuhn H, Kuhnert R, Scheidt-Nave C. 12-month prevalence of known chronic obstructive pulmonary disease (COPD) in Germany. J Health Monit. 2017;2:43–50 doi:10.17886/RKI-GBE-2017-065
   PubMedGoogle Scholar
• Forum of International Respiratory Societies. The global impact of respiratory disease. Third edition; 2021. Available from: https://www.firsnet.org/images/publications/FIRS_Master_09202021.pdf. Accessed March 13, 2022
   Google Scholar
• Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–458. doi:10.1016/S2213-2600(21)00511-7
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report; 2023. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed March 13, 2022
   Google Scholar
• Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals. Int J Chron Obstruct Pulmon Dis. 2019;14:391–401. doi:10.2147/COPD.S173901
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7(2):00950–02020. doi:10.1183/23120541.00950-2020
   PubMedGoogle Scholar
• European Medicines Agency. Trelegy Ellipta summary of product characteristics; 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/trelegy-ellipta-epar-product-information_en.pdf. Accessed March 13, 2022
   Google Scholar
• European Medicines Agency. Trimbow summary of product characteristics; 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/trimbow-epar-product-information_en.pdf. Accessed March 13, 2022
   Google Scholar
• Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72. doi:10.1186/1471-2466-13-72
   PubMed Web of Science ®Google Scholar
• van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079. doi:10.1038/npjpcrm.2016.79
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Rothnie KJ, Banks V, et al. Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting. Int J Chron Obstruct Pulmon Dis. 2022;17:2417–2429. doi:10.2147/COPD.S370540
   PubMed Web of Science ®Google Scholar
• Collier DJ, Wielders P, van der Palen J, et al. Critical error frequency and the impact of training with inhalers commonly used for maintenance treatment in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1301–1313. doi:10.2147/COPD.S224209
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS. Characteristics of new users of single- and multiple-inhaler triple therapy for COPD in primary care in England. Int J Chron Obstruct Pulmon Dis. 2022;17:1455–1466. doi:10.2147/COPD.S338436
   PubMed Web of Science ®Google Scholar
• Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. Respir Med. 2018;142:73–80. doi:10.1016/j.rmed.2018.07.009
   PubMed Web of Science ®Google Scholar
• Wu B, Mannino D, Mu G, Stiegler M, Bogart M. Patient and clinical demographics of new users to single-inhaler triple therapy in patients with chronic obstructive pulmonary disease. Pulm Ther. 2022;8(2):195–208. doi:10.1007/s41030-022-00189-6
   PubMedGoogle Scholar
• Xu X, Milea D, Navarro Rojas AA, et al. A real-world analysis of treatment patterns and clinical characteristics among patients with COPD who initiated multiple-inhaler triple therapy in New Zealand. Int J Chron Obstruct Pulmon Dis. 2021;16:1835–1850. doi:10.2147/COPD.S295183
   PubMed Web of Science ®Google Scholar
• Buhl R, Wilke T, Picker N, et al. Real-world treatment of patients newly diagnosed with chronic obstructive pulmonary disease: a retrospective German claims data analysis. Int J Chron Obstruct Pulmon Dis. 2022;17:2355–2367. doi:10.2147/COPD.S375190
   PubMed Web of Science ®Google Scholar
• World Health Organization. Defined daily dose (DDD); 2023. Available from: https://www.who.int/tools/atc-ddd-toolkit/about-ddd. Accessed March 13, 2022
   Google Scholar
• The Information System of the Federal Health Monitoring. DDD (defined daily dose); 2023. Available from: https://www.gbe-bund.de/glossary/DDD_defined_daily_dose.html. Accessed March 13, 2022
   Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi:10.2147/COPD.S91694
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Nakamura H, Takahashi S, et al. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:1053–1059. doi:10.2147/COPD.S79864
   PubMed Web of Science ®Google Scholar
• Papala M, Kerenidi N, Gourgoulianis KI. Everyday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPD. Prim Care Respir J. 2013;22(3):362–364. doi:10.4104/pcrj.2013.00073
   PubMedGoogle Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106(7):989–997. doi:10.1016/j.rmed.2012.03.008
   PubMed Web of Science ®Google Scholar
• Burgel PR, Deslée G, Jebrak G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J. 2014;43(4):1201–1203. doi:10.1183/09031936.00162313
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma global strategy for asthma management and prevention; 2023. Available from: https://ginasthma.org/2023-gina-main-report/. Accessed December 14, 2023
   Google Scholar
• European Medicines Agency. Trixeo Aerosphere summary of product characteristics; 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/trixeo-aerosphere-epar-product-information_en.pdf. Accessed March 13, 2022
   Google Scholar